Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy

Fig. 2

Hazard ratios for death in non-oncogene positive (A) advanced and/or metastatic NSCLC, (B) ALK-positive and (C) EGFR-positive patients in years 2013 to 2019 relative to 2012, unadjusted, adjusting only for differences in baseline characteristics and adjusting for both baseline characteristics and (A) first and/or second line immunotherapy, (B) first and/or second/third generation ALK inhibitor use, and (C) first/second and/or third generation EGFR inhibitor use

Back to article page